Dampening the Reproductive Axis With Continuous Kisspeptin
Reproductive Disorder, PCOS, Polycystic Ovary Syndrome
About this trial
This is an interventional other trial for Reproductive Disorder focused on measuring reproductive disorders, kisspeptin, PCOS, GnRH
Eligibility Criteria
Ages 18-45 years A history of clinical diagnosis of PCOS or equivalent clinical features BMI >18.5 and <35 kg/m2 Normal blood pressure (systolic BP < 140 mm Hg, diastolic > 90 mm Hg) Laboratory studies: Negative human chorionic gonadotropin (hCG) pregnancy test prior to kisspeptin administration Hemoglobin no less than 0.5 g/dL below the lower limit of the reference range for healthy women Not using hormonal medication or willing to complete an appropriate washout for that particular medication and its method of administration No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration No history of a medication reaction that required emergency medical care No excessive alcohol consumption (>10 drinks/week) and/or ongoing use of illicit drugs • Any current use of marijuana will be evaluated by a study medical professional to determine if it is expected to impact study participation Not pregnant or trying to become pregnant Not breastfeeding No history of bilateral oophorectomy (both ovaries removed)
Sites / Locations
- Massachusetts General HospitalRecruiting
Arms of the Study
Arm 1
Experimental
kisspeptin, GnRH
IV administration of kisspeptin 112-121; 24-hour infusion. IV administration of GnRH; up to one bolus.